Benitec Biopharma Inc. (NASDAQ:BNTC – Get Rating) saw a significant increase in short interest during the month of May. As of May 31st, there was short interest totalling 8,000 shares, an increase of 281.0% from the May 15th total of 2,100 shares. Approximately 0.1% of the shares of the company are sold short. Based on […]
Benitec Biopharma Inc. (NASDAQ:BNTC – Get Rating) was the target of a significant increase in short interest in May. As of May 31st, there was short interest totalling 8,000 shares, an increase of 281.0% from the May 15th total of 2,100 shares. Based on an average daily trading volume, of 23,500 shares, the days-to-cover ratio […]
Wall Street analysts forecast that Benitec Biopharma Inc. (NASDAQ:BNTC – Get Rating) will post earnings of ($0.28) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Benitec Biopharma’s earnings. Benitec Biopharma posted earnings per share of ($60.00) during the same quarter last year, which indicates a positive year-over-year […]
Benitec Biopharma (NASDAQ:BNTC – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Wednesday, Zacks.com reports. The firm presently has a $1.00 price objective on the biotechnology company’s stock. Zacks Investment Research‘s target price would suggest a potential upside of 10.12% […]
Benitec Biopharma (NASDAQ:BNTC – Get Rating) and Affymax (OTCMKTS:AFFY – Get Rating) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, dividends, analyst recommendations and risk. Institutional and Insider Ownership 20.2% of Benitec Biopharma shares are owned […]